Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.82% $0.241
America/New_York / 15 jun 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1.778 mill |
EPS: | -0.580 |
P/E: | -0.416 |
Earnings Date: | Aug 09, 2023 |
SharesOutstanding: | 7.38 mill |
Avg Daily Volume: | 0.268 mill |
RATING 2023-06-15 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
Revenue | n/a | n/a | ||||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.416 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.07x |
Company: PE -0.416 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.198 - 0.284 ( +/- 17.84%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-01-26 | Dyer Jeffrey Hansen | Buy | 42 986 | Common Stock |
2023-01-26 | Dyer Jeffrey Hansen | Sell | 200 | Stock option (right to buy) |
2023-01-26 | Dyer Jeffrey Hansen | Sell | 0 | Common Stock |
2023-01-12 | Nolet Chris | Sell | 36 497 | Common Stock |
2023-01-12 | Nolet Chris | Sell | 3 078 | Stock option (right to buy) |
INSIDER POWER |
---|
53.84 |
Last 99 transactions |
Buy: 3 157 109 | Sell: 846 689 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.241 (-0.82% ) |
Volume | 8.32 mill |
Avg. Vol. | 0.268 mill |
% of Avg. Vol | 3 107.29 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.